1. Home
  2. LRFC vs XLO Comparison

LRFC vs XLO Comparison

Compare LRFC & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LRFC
  • XLO
  • Stock Information
  • Founded
  • LRFC 2013
  • XLO 2016
  • Country
  • LRFC United States
  • XLO United States
  • Employees
  • LRFC N/A
  • XLO N/A
  • Industry
  • LRFC Finance: Consumer Services
  • XLO Biotechnology: Pharmaceutical Preparations
  • Sector
  • LRFC Finance
  • XLO Health Care
  • Exchange
  • LRFC Nasdaq
  • XLO Nasdaq
  • Market Cap
  • LRFC 50.2M
  • XLO 42.2M
  • IPO Year
  • LRFC 2013
  • XLO 2021
  • Fundamental
  • Price
  • LRFC $18.86
  • XLO $0.69
  • Analyst Decision
  • LRFC
  • XLO Buy
  • Analyst Count
  • LRFC 0
  • XLO 1
  • Target Price
  • LRFC N/A
  • XLO $4.00
  • AVG Volume (30 Days)
  • LRFC 11.2K
  • XLO 620.2K
  • Earning Date
  • LRFC 08-07-2025
  • XLO 08-07-2025
  • Dividend Yield
  • LRFC 7.58%
  • XLO N/A
  • EPS Growth
  • LRFC N/A
  • XLO N/A
  • EPS
  • LRFC N/A
  • XLO N/A
  • Revenue
  • LRFC $20,544,000.00
  • XLO $9,274,000.00
  • Revenue This Year
  • LRFC N/A
  • XLO $300.08
  • Revenue Next Year
  • LRFC N/A
  • XLO $1.87
  • P/E Ratio
  • LRFC N/A
  • XLO N/A
  • Revenue Growth
  • LRFC 3.11
  • XLO N/A
  • 52 Week Low
  • LRFC $16.57
  • XLO $0.62
  • 52 Week High
  • LRFC $26.00
  • XLO $1.70
  • Technical
  • Relative Strength Index (RSI)
  • LRFC 56.05
  • XLO 43.13
  • Support Level
  • LRFC $18.53
  • XLO $0.66
  • Resistance Level
  • LRFC $19.00
  • XLO $0.69
  • Average True Range (ATR)
  • LRFC 0.39
  • XLO 0.03
  • MACD
  • LRFC 0.18
  • XLO 0.00
  • Stochastic Oscillator
  • LRFC 77.87
  • XLO 29.23

About LRFC Logan Ridge Finance Corporation

Logan Ridge Finance Corp an externally managed non-diversified closed-end management investment company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company offers customized financing to business owners, management teams, and financial sponsors for change of ownership transactions, recapitalizations, strategic acquisitions, business expansion, and other growth initiatives.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Share on Social Networks: